SCHEDULE: Vanguard Group Amends Amylyx Stake to Zero

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Amylyx Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for Amylyx Pharmaceuticals Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Amylyx Pharmaceuticals Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc., which became effective on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, reflecting an internal organizational change at Vanguard rather than a direct positive or negative assessment of Amylyx Pharmaceuticals Inc.

Positives

• The filing provides clear and transparent disclosure regarding The Vanguard Group's updated beneficial ownership structure following an internal realignment.

Negatives

• The Vanguard Group, as the parent entity, no longer directly reports beneficial ownership in Amylyx Pharmaceuticals Inc., which could be misinterpreted as a complete divestment rather than a structural reporting change.

Risks

• There is a potential for market misinterpretation if investors do not fully understand that the 0% beneficial ownership reported by The Vanguard Group is due to an internal realignment and disaggregated reporting by subsidiaries, rather than a negative investment decision regarding Amylyx Pharmaceuticals Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Amylyx Pharmaceuticals Inc.'s future performance or The Vanguard Group's future investment intentions beyond the current reporting structure.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Industry Context

StockSavvy.ai notes that such internal realignments are common among large asset managers like The Vanguard Group, often aimed at optimizing operational efficiency or regulatory compliance. While Vanguard itself now reports zero direct beneficial ownership, its various funds and subsidiaries may still hold significant stakes in Amylyx Pharmaceuticals Inc., which would be reported under their respective Schedule 13G filings. This disaggregation provides more granular insight into specific fund holdings rather than a consolidated view from the parent entity.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for changes in beneficial ownership, consistent with SEC requirements for institutional investors.
• Large institutional investors such as BlackRock, State Street, and Fidelity also frequently file Schedule 13G amendments to reflect changes in their holdings or internal reporting structures.
• The disaggregation of reporting by subsidiaries is a common practice among diversified financial groups, allowing for more specific reporting by individual investment vehicles or funds.

Stakeholder Impact

• Shareholders of Amylyx Pharmaceuticals Inc. may initially perceive a large institutional investor reducing its stake as negative, but understanding the internal realignment context is crucial to avoid misinterpretation.
• The Vanguard Group's clients and investors may benefit from more granular reporting, potentially offering clearer insights into specific fund holdings within the group.

Next Steps

• Subsidiaries or business divisions of The Vanguard Group, Inc. are expected to report their beneficial ownership in Amylyx Pharmaceuticals Inc. separately in future filings.

Key Dates

Recommendation

The filing is administrative, reflecting an internal organizational change at The Vanguard Group rather than a change in investment thesis for Amylyx Pharmaceuticals Inc. While Vanguard's direct beneficial ownership is now zero, its subsidiaries may still hold shares. Therefore, this filing alone does not warrant a change in investment recommendation for Amylyx, and a 'hold' stance is appropriate pending further information on subsidiary holdings or company-specific news.

Keywords

Amylyx Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Realignment